COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPß pathway and PDK1 stabilization

Yi Hui Wu, Tzu Hao Chang, Yu Fang Huang, Chien Chin Chen, Cheng Yang Chou

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Chemoresistance to anticancer drugs substantially reduces survival in epithelial ovarian carcinoma (EOC). Here, microarray analysis showed that collagen type XI alpha 1 (COL11A1) is a chemotherapy response-associated gene. Chemoresistant cells expressed higher COL11A1 and c/EBPß than chemosensitive cells. COL11A1 or c/EBPß downregulation suppressed chemoresistance, whereas COL11A1 overexpression attenuated sensitivity to cisplatin and paclitaxel.The c/EBPß binding site in the COL11A1 promoter was identified as the major determinant of cisplatin- and paclitaxel-induced COL11A1 expression. Immunoprecipitation and immunofluorescence showed that in resistant cells, Akt and PDK1 were highly expressed and that anticancer drugs enhanced binding activity between COL11A1 and PDK1 binding and attenuated PDK1 ubiquitination and degradation. Conversely, chemosensitive cells showed decreased activity of COL11A1 binding to PDK1 and increased PDK1 ubiquitination, which were reversed by COL11A1 overexpression. Analysis of 104 EOC patients showed that high COL11A1 mRNA levels are significantly associated with poor chemoresponse and clinical outcome.

Original languageEnglish
Pages (from-to)23748-23763
Number of pages16
JournalOncotarget
Volume6
Issue number27
DOIs
Publication statusPublished - 2015

    Fingerprint

Keywords

  • Akt
  • Chemoresistance
  • Collagen type XI alpha 1
  • Epithelial ovarian carcinoma
  • PDK1

ASJC Scopus subject areas

  • Oncology

Cite this